TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04464733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01008397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHIST NDC#58407-012-01
Description: Oral tablet containing chlorpheniramine tannate 12mg.
Study: NCT00993876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: 20 to 30 mg per day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reboxetine
Description: 4 to 8 mg per day for 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interpersonal psychotherapy
Study: NCT04464733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01303354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Transforaminal Epidural Steroid Injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Transforaminal Epidural Steroid Injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Transforaminal Epidural Steroid Injection
Study: NCT03320226

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic 10 (Nature's Bounty)
Description: The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
Study: NCT03222011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard (single) endoscopic stricture dilatation
Description: single endoscopic stricture dilatation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive endoscopic stricture dilatation
Description: 3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
Study: NCT00735254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser
Description: patient will have scar treated with pulsed dye laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Affirm Laser
Description: patient will have scar treated with Affirm laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: combined PDL and Affirm Lasers
Description: patient will have scar treated with Affirm and pulsed dye lasers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patient will receive no treatment
Study: NCT02321358

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Materials
Description: Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Materials
Description: Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
Study: NCT03932617

Intervention type: DEVICE
Intervention: end tidal carbon dioxide by capnography
Description: Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states.
Study: NCT04241341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
Description: Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
Study: NCT03959254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy post-surgical protocol for femoroacetabular impingement
Description: The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy post-surgical protocol for femoroacetabular impingement
Description: The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise.
Study: NCT04790396

Intervention type: DEVICE
Intervention: Carotid ultrasound under pulsed-wave doppler mode
Description: Carotid ultrasound under pulsed-wave doppler mode to check whether carotid pulse is present
Study: NCT04241341

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction
Description: Current standard treatment at Memorial Sloan Kettering \[MSK\]).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life questionnaires
Description: Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
Study: NCT01672229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
Study: NCT02161029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible drill biopsy instrument
Description: Biopsies taken with the new drill biopsy instrument for flexible endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional biopsy instrument
Description: Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
Study: NCT04241341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life questionnaires
Description: Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: measured by arm volume
Description: Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measured by arm volume
Description: Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
Study: NCT04374318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: INTRATHECAL AND INTRAVENOUS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: INTRATHECAL AND INTRAVENOUS
Study: NCT01245413

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: Adhesive to stoma bag

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Athena
Description: Adhesive to stoma bag
Study: NCT02851147

Intervention type: DEVICE
Intervention: SL-D301
Description: Slit Lamp

Intervention type: DEVICE
Intervention: DC-4
Description: Digital Camera Attachment

Intervention type: DEVICE
Intervention: SL-3G
Description: Slit Lamp
Study: NCT04454164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: platelet rich plasma
Study: NCT04153786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporary changes in an already-implanted medical device (biventricular pacemaker)
Description: During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits.
Study: NCT03953664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental-Exercise training
Description: Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental-Exercise training
Description: Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental-Exercise training
Description: Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
Study: NCT02117505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2
Description: Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5\*30 mg tablet=150 mg) in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1
Description: Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5\*30 mg tablet=150 mg) in one of the treatment periods.
Study: NCT00090753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Description: Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
Study: NCT03183141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SER-109
Description: SER-109, an oral, biologically derived, live microbiome therapeutic that comprises purified bacterial spores
Study: NCT01898598

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo to vismodegib for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
Study: NCT03092388

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi Frequency Bioimpedance Analysis (mfBIA)
Description: Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi Frequency Bioimpedance Analysis (mfBIA)
Description: Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography/Polygraphy (PSG/PG)
Description: Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography/Polygraphy (PSG/PG)
Description: Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Capillary Blood Gas Analysis (CBGA)
Description: CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Capillary Blood Gas Analysis (CBGA)
Description: CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tilting Table with Hemodynamic Monitoring
Description: A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
Study: NCT04454164

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: serum physiologic
Study: NCT02672761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR meditation
Description: Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBT training
Description: A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session.
Study: NCT01902238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol-lipiodol mixture ablation
Description: By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
Study: NCT02830061

Intervention type: OTHER
Intervention: Interviews
Description: Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
Study: NCT02334631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Volume Simethicone
Description: High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Volume Simethicone
Description: Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
Study: NCT04409600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Gait Retraining
Description: The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Gait Retraining
Description: The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
Study: NCT02672761

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
Study: NCT03109327

Intervention type: DIAGNOSTIC_TEST
Intervention: Melanoma Detection System -MDS
Description: Imaging of lesion using the MDS test.
Study: NCT04409600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Gait Retraining
Description: The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Based Gait Retraining
Description: The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.